BIO from the BAYOU · 2026-06-03 · 28 min
Math doesn’t have to be intimidating, especially when it’s the kind that helps fund companies and move science forward. In this episode, host Elaine Hamm, PhD, is joined by Isaiah Reeves, PhD, Biomedical Analyst at Solas BioVentures, for a practical and approachable deep dive into venture math. Drawing on his background as a scientist turned investor, Isaiah breaks down the core financial concepts every biotech founder should understand: from valuations and dilution to IRR, cap tables, and deal terms. The conversation offers real-world guidance for navigating fundraising, choosing the right partners, and avoiding common pitfalls that can derail long-term value creation. In this episode, you’ll learn: How venture capitalists think about valuations, dilution, and returns, and why fully diluted post-money matters. Key metrics like IRR and DPI, and how they influence investment decisions and fund performance. Common deal terms and cap table “red flags” founders should watch out for as they raise capital.
Episode 143: Why Animal Health Is the Next Frontier for Biotech Innovation72 / 100Episode 142: How ARPA-H is Reimagining Women’s Health and Maternal CareEpisode 141: From Bench Science to Biotech Investment and Venture FundingEpisode 140: The Growing Role of AI in Healthcare, Biotech, and Drug DevelopmentEpisode 138: Building Biotech Across Borders - Translational Science, Hearing Loss, and the Reality of Drug Development